Evotec AG and Facio Therapies announced today that they have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD, a muscle wasting disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/facio-partners-with-evotec-and-initiates-fshd-drug-discovery-programme-5281